Pharmaceutical and Biotechnology Regulatory Law
Drug companies face pressure from many directions — from a foreboding regulatory landscape, from competitors with alternative brands or generics, from insurers pushing back on prescription drug costs and reimbursement. At the same time, they can find opportunities in maximizing the benefits of statutes that encourage new drug development. Whether you’re a global pharmaceuticals company or a biotechnology startup, accomplishing business goals in such a highly regulated industry requires practical, integrated legal analysis and advice.
We are creative in solving your problems thanks to our background and experience. We not only know the law, we know the nuances of the law because many of our lawyers have worked in the U.S. Food and Drug Administration. Others have worked in industry, which means we also understand your business, the science behind your business, and your marketplace. And to provide integrated advice across jurisdictions, our pharma/biotech lawyers in Europe, Asia, and Latin America collaborate closely with our U.S. team, which is the largest in the nation dedicated to providing regulatory legal services to the industry.
Our services are as varied as the challenges you face. We offer timely, effective counsel on matters that include product development, approval, post-approval compliance, and the development of next-generation products. Our lawyers concentrate on particular areas of the law, such as advertising, manufacturing compliance, regulatory exclusivities, and controlled substances. And when your issues overlap with other disciplines, such as intellectual property, litigation, or healthcare compliance, we reach across the firm to tap into the needed expertise, especially in our strong health practice.
Convinced FDA to give 5-year exclusivity to fixed dose combination products that include a new chemical entity and a previously approved active ingredient.
Successfully sued FDA to overturn denial of orphan drug exclusivity.
Wrote successful petition seeking denial of “A” rating to purported generic products.
Help respond to FDA Form 483 observations, warning letter to close out FDA investigation.
Negotiate settlement of FDA lawsuit alleging cGMP noncompliance.
Conduct internal investigation of promotional practices and help develop and implement enhanced practices.
Develop SOPs for compliant promotional activities.
Develop and negotiate with FDA over the elements of a REMS.
Represent reference product sponsor in shared REMS negotiations with generics.
Audit clinical trial study reports to ensure compliance with adverse event reporting obligations.
Counsel client on labeling changes proposed in response to emerging safety signals.
Help develop product approval strategy.
Help draft FDA meeting requests, briefing packages.
Advise client on standards for interchangeability of biosimilars.
Advise on FDA/DEA interplay during drug development and approval process, scheduling under CSA.
Conduct due diligence of FDA and EU regulatory law for IPO.
Advise private equity firm on FDA regulatory aspects of potential investments.
David Fox Named LMG Life Sciences Regulatory Lawyer of the Year
Philip Katz Receives Food and Drug Law Institute Distinguished Service and Leadership Award
7 of our 10 Partners Previously Worked for the U.S. FDA and/or DOJ.
We are the largest law firm practice focused specifically on drug and biologic regulatory law in the U.S.
Latest thinking and events
01 December 2016